Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News BioMerieux given US green light for bacterial test

BioMerieux given US green light for bacterial test

19th October 2007

BioMerieux has got the go-ahead to market a test for use on critically ill patients.

The world leader in the in vitro diagnostics field received clearance from the US Food and Drug Administration regarding VIDAS BRAHMS PCT, which will be used as an aid to assess the risk of patients’ progression to severe sepsis and septic shock.

PCT, a biological marker for bacterial infections well-known in Europe where it is used in hospitals and healthcare settings, has not yet been subject to an automated measuring test by a US company.

BioMerieux has pointed out that as the progression of severe bacterial infections is affected by how early the patient receives appropriate treatment, measuring PCT levels is valuable in intensive care units where sepsis represents a major health challenge.

"Sepsis is a key area of focus for BioMerieux and we are pleased to make this high medical value test available to a great number of clinicians on our widely installed VIDAS platform," commented Stephane Bancel, chief executive officer for BioMerieux.

"PCT testing can be used as an aid to provide an early indication of need for aggressive interventions and can potentially improve patient outcome and increase chances of survival," he added.

Earlier this month BioMerieux announced the launch of another VIDAS test to help the diagnosis and prognosis of heart failure.ADNFCR-1050-ID-18323241-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.